January 28, 2022
Life Sciences
  • Biogen Inc. will sell its nearly 50 percent stake in Samsung Bioepis, a joint venture with Samsung Biologics to develop biosimilar drugs, to its partner for at least $2.25 billion. The deal will give Biogen access to $1 billion in cash upon closing as the pharma company grapples with the lackluster launch of its controversial Alzheimer’s disease drug Aduhelm. Biogen will continue to help sell the venture’s existing biosimilars after the deal closes. (Article here)